Clene Stock (NASDAQ:CLNN)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$4.66

52W Range

$3.82 - $12.00

50D Avg

$5.40

200D Avg

$6.63

Market Cap

$32.64M

Avg Vol (3M)

$71.56K

Beta

0.41

Div Yield

-

CLNN Company Profile


Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

82

IPO Date

Oct 18, 2018

Website

CLNN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22Dec 21Dec 20
Royalty$144.00K$153.00K$30.00K
Product$316.00K$570.00K$176.00K

Fiscal year ends in Dec 23 | Currency in USD

CLNN Financial Summary


Dec 23Dec 22Dec 21
Revenue$654.00K$473.00K$723.00K
Operating Income$-40.54M$-45.33M$-45.28M
Net Income$-49.50M$-15.28M$-9.74M
EBITDA$-38.84M$-45.07M$-47.52M
Basic EPS$-0.47$-0.23$-0.16
Diluted EPS$-0.47$-0.23$-0.16

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
NGMNGM Biopharmaceuticals, Inc.
CYTCyteir Therapeutics, Inc.
NUVBNuvation Bio Inc.
NXTCNextCure, Inc.
IKNAIkena Oncology, Inc.
FHTXFoghorn Therapeutics Inc.
MLYSMineralys Therapeutics, Inc.
IPSCCentury Therapeutics, Inc.
SNSESensei Biotherapeutics, Inc.
CSBRChampions Oncology, Inc.
GRPHLENZ Therapeutics, Inc.
MNOVMediciNova, Inc.
HOWLWerewolf Therapeutics, Inc.
NKTXNkarta, Inc.
MOLNMolecular Partners AG
KZRKezar Life Sciences, Inc.
MACKMerrimack Pharmaceuticals, Inc.
IMNMImmunome, Inc.
ELYMEliem Therapeutics, Inc.